<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00326625</url>
  </required_header>
  <id_info>
    <org_study_id>ALS-GA-201</org_study_id>
    <nct_id>NCT00326625</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <brief_summary>
    <textblock>
      Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under
      the skin, for the treatment of ALS. The study drug is a higher dose formulation of CopaxoneÂ®
      (20 mg/ml GA), a marketed medication, approved for the treatment of relapsing-remitting
      multiple sclerosis. GA is an immunomodulating drug that has anti inflammatory and
      neuroprotective properties, which are believed to be of therapeutic value in ALS. The study
      treatment duration is 1 year (52 weeks).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2006</start_date>
  <completion_date type="Actual">July 31, 2008</completion_date>
  <primary_completion_date type="Actual">June 30, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in ALS Functional Rating Score (ALSFRS-R) at Each Visit</measure>
    <time_frame>Bseline, Weeks 4, 8, 12, 17, 22, 26, 31, 36, 40, 44, 48, 52</time_frame>
    <description>Change from baseline to each visit in ALSFRS-R score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Death/Tracheostomy/Permanent Assisted Ventilation</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>40 mg glatiramer acetate (GA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-filled syringe of 40 mg glatiramer acetate (GA) for injection, administered subcutaneously once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pre-filled syringe of matching placebo, administered subcutaneously once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg glatiramer acetate</intervention_name>
    <description>parenteral drug</description>
    <arm_group_label>40 mg glatiramer acetate (GA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria.

          2. Subject has experienced his/her first ALS symptoms within 3 years prior to the
             screening visit.

          3. Slow VC test equal or greater than 70% of the predicted value.

          4. The sum of the 3 respiratory items on the ALSFRS-R must total at least 10 points.

          5. Stable dose of riluzole for at least 8 weeks prior to screening.

          6. Age - 18-70 (inclusive).

        Exclusion Criteria:

          1. The use of invasive or non-invasive ventilation.

          2. Subject having undergone gastrostomy.

          3. Subject with any clinically significant or unstable medical condition.

          4. Subjects participating in any other clinical trial (within 12 weeks prior to screening
             and thereafter).

          5. Additional criteria per protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merav Bassan, PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Teva Pharmaceuticals Industries LTD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Benelux</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Germany</name>
      <address>
        <city>Morfelden-Walldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Israel</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Italy</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva UK</name>
      <address>
        <city>Aylesbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2006</study_first_submitted>
  <study_first_submitted_qc>May 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2006</study_first_posted>
  <last_update_submitted>February 17, 2018</last_update_submitted>
  <last_update_submitted_qc>February 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

